Akexis
Revolutionizing Cancer Care
We believe in a future where cancer is a survivable disease.
Confronting a Critical Gap in Cancer Care
Cachexia is a severe, debilitating condition affecting 80% of late-stage cancer patients, contributing directly to 30% of cancer-related deaths. Characterized by extreme weight loss, muscle wasting, and immune system dysfunction, it drastically reduces patients' ability to respond to and tolerate anti-tumor treatments like immunotherapy and chemotherapy. Despite its devastating impact, there are currently no FDA-approved treatments, leaving a critical gap in care for those battling advanced cancer.
Revolutionizing Cancer Care with Targeted Solutions
Akexis is pioneering the first therapy targeting the cause of cancer cachexia, directly addressing the underlying immune system dysfunction that drives this condition. By stopping and reversing the progression of cachexia, our treatment improves survival and empowers patients to better withstand and respond to therapies like immunotherapy and chemotherapy, improving both anti-tumor efficacy and quality of life. Our mission is to transform the standard of care and give patients the strength to fight back against advanced cancer.
